Therapeutics News and Research

RSS

Research team identifies new therapeutic target for castration-resistant prostate cancer

A collaborative research team has linked the development of castration-resistant prostate cancer and resistance to treatment to a lack of androgen receptor expression in prostate cancer cells, identifying a new therapeutic target for one of the deadliest forms of cancer among men.

7 Sep 2018

Ground-breaking therapeutic process can destroy bowel cancer cells

Researchers at Queen's University Belfast have discovered a ground-breaking therapeutic process that can target and kill bowel cancer cells, which may improve survival rates for bowel cancer patients globally.

6 Sep 2018

Natural plant compound exploits newly identified Achilles' heel in uveal melanoma

A natural plant compound exploits a newly identified Achilles' heel in a cancer of the eye, uveal melanoma. In human cancer cells growing in the lab, the compound shuts down the overactive signaling that drives uveal melanoma cell growth, according to researchers at Washington University School of Medicine in St. Louis.

6 Sep 2018

USC scientists develop new way to identify molecular markers of breast cancer tumors

A research team led by USC scientists has developed a new way to identify molecular markers of breast cancer tumors, a potentially life-saving breakthrough that could lead to better treatment for millions of women.

6 Sep 2018

Investigators identify group of blood metabolites that could help detect autism

Investigators at the UC Davis MIND Institute and NeuroPointDX, a division of Stemina Biomarker Discovery, have identified a group of blood metabolites that could help detect some children with autism spectrum disorder

6 Sep 2018

BeiGene collaborates with SpringWorks to evaluate new combinational therapy for solid tumors

BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, and SpringWorks Therapeutics, a clinical-stage rare disease and oncology company focused on sourcing and developing innovative treatments for underserved patient populations, announced today that the companies have entered into a global clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining BeiGene's investigational RAF dimer inhibitor, lifirafenib and SpringWorks Therapeutics' investigational MEK inhibitor, PD-0325901, in patients with advanced solid tumors.

6 Sep 2018

Researchers discover natural plant compound that shuts down uveal melanoma cell growth

A natural plant compound exploits a newly identified Achilles' heel in a cancer of the eye, uveal melanoma.

6 Sep 2018

Global warming may increase likelihood of HFMD transmission

Hand, foot, and mouth disease is a common childhood viral infection that is most common in warmer summer months.

6 Sep 2018

Researchers hope to translate mRNA drugs from lab to medicine cabinet

In cells, ribosomes translate messenger RNA into proteins. And in the nascent field of mRNA therapeutics, researchers and investors are hoping to translate mRNA drugs from the lab to the medicine cabinet.

6 Sep 2018

American Pain Society encouraged by progress toward increased funding for pain research

It's been more than two years since the National Institutes of Health released its National Pain Strategy, a comprehensive population health-level strategy for pain, and a year since announcing its Federal Pain Strategy, a long-term strategic plan for pain research.

6 Sep 2018

Hypertension drugs may be used to preserve memory of lupus patients

Researchers from The Feinstein Institute for Medical Research have discovered that the activation of brain cells called microglia likely contributes to the memory loss and other cognitive impairments suffered by many patients with systemic lupus erythematosus.

5 Sep 2018

Phase 2 clinical study reports best outcomes to date for older Hodgkin lymphoma patients

Recently published results of a phase 2 clinical trial have shown the best outcomes to date for newly diagnosed older Hodgkin lymphoma patients treated with brentuximab vedotin given before and after doxorubicin, vinblastine and dacarbazine chemotherapy, which is the standard of care.

5 Sep 2018

Gene therapy for rare genetic blindness wins prestigious Champalimaud Vision award

A team of seven researchers collaborating from United States and Britain have found a way to use gene therapy to cure a rare form of childhood blindness that occurs due to a genetic predisposition.

5 Sep 2018

Dopamine receptor study opens door to targeted treatments for neuropsychiatric disorders

New work from researchers at Columbia University Vagelos College of Physicians and Surgeons sheds light on how dopamine receptors signal within cells, opening the door for more targeted--and more tolerable--therapeutics to treat an array of neuropsychiatric disorders.

4 Sep 2018

Research: Faster progression of disablement in stiff person syndrome than originally believed

The American Association of Neuromuscular & Electrodiagnostic Medicine is honoring Goran Rakocevic, MD, with the 2018 Best Abstract Award for his abstract, Quantitative Clinical and Autoimmune Assessments in Stiff Person Syndrome: Evidence for a Progressive Disorder.

3 Sep 2018

Arrowhead completes dosing of ARO-AAT Phase 1 study to treat rare genetic liver disease

Arrowhead Pharmaceuticals Inc. today announced that it has completed dosing of a Phase 1 clinical study of ARO-AAT, the company's second generation subcutaneously administered RNA interference therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.

31 Aug 2018

Groundbreaking CURATE.AI platform halts progression of advanced cancer

A translational research team led by the National University of Singapore has harnessed CURATE.AI, a powerful artificial intelligence platform, to successfully treat a patient with advanced cancer, completely halting disease progression.

31 Aug 2018

NUS researchers harness AI platform to treat patient with advanced cancer

31 Aug 2018

Leukogene receives STTR grant to optimize compound for treatment-resistant multiple myeloma

A $2 million phase 2 Small Business Technology Transfer grant to optimize a promising new compound that has shown efficacy in preclinical studies against treatment-resistant multiple myeloma has been awarded to a Medical University of South Carolina startup company, Leukogene Therapeutics, Inc., in collaboration with MUSC researcher and company founder, Nathan G. Dolloff, Ph.D. Dolloff is an assistant professor in the Department of Cell and Molecular Pharmacology & Experimental Therapeutics at MUSC and a member of MUSC Hollings Cancer Center.

31 Aug 2018

EC grants marketing authorization for ONPATTRO (patisiran) in Europe

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that the European Commission (EC) has granted marketing authorization for ONPATTRO (patisiran) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults with stage 1 or stage 2 polyneuropathy.

30 Aug 2018

Therapeutics News and Research

Research team identifies new therapeutic target for castration-resistant prostate cancer

Ground-breaking therapeutic process can destroy bowel cancer cells

Natural plant compound exploits newly identified Achilles' heel in uveal melanoma

USC scientists develop new way to identify molecular markers of breast cancer tumors

Investigators identify group of blood metabolites that could help detect autism

BeiGene collaborates with SpringWorks to evaluate new combinational therapy for solid tumors

Researchers discover natural plant compound that shuts down uveal melanoma cell growth

Global warming may increase likelihood of HFMD transmission

Researchers hope to translate mRNA drugs from lab to medicine cabinet

American Pain Society encouraged by progress toward increased funding for pain research

Hypertension drugs may be used to preserve memory of lupus patients

Phase 2 clinical study reports best outcomes to date for older Hodgkin lymphoma patients

Gene therapy for rare genetic blindness wins prestigious Champalimaud Vision award

Dopamine receptor study opens door to targeted treatments for neuropsychiatric disorders

Research: Faster progression of disablement in stiff person syndrome than originally believed

Arrowhead completes dosing of ARO-AAT Phase 1 study to treat rare genetic liver disease

Groundbreaking CURATE.AI platform halts progression of advanced cancer

NUS researchers harness AI platform to treat patient with advanced cancer

Leukogene receives STTR grant to optimize compound for treatment-resistant multiple myeloma

EC grants marketing authorization for ONPATTRO (patisiran) in Europe

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News